Abstract
X-box binding protein1 (XBP1) especially exerts its fundamental effects in the cellular organelle endoplasmic reticulum (ER) via affecting three trans-membrane stress sensor proteins: PKRlike ER kinase (PERK), inositol-requiring enzyme 1(IRE1) and activating transcription factor 6(ATF6). At the center of XBP1’s broad effects is its remarkable metabolic housekeeper function. XBP1 decreased glucose dysfunction via funneling its effects on improving insulin sensitivity and stimulating insulin secretion. However, XBP1 also yields its double-edged effects, driving the transformation from excess glucose to lipid, which is a key contribution to obesity and T2DM. In this review, we highlight the vital mechanism of XBP1 in manipulating glucose and lipid metabolism involved by multiple signaling pathways.
Keywords: Metabolic regulator/housekeeper, XBP1, PI3K, ER stress, IRE1α, insulin.
Graphical Abstract
Current Protein & Peptide Science
Title:The Multiple Roles of XBP1 in Regulation of Glucose and Lipid Metabolism
Volume: 18 Issue: 6
Author(s): Jianjing Yang, Xiaojie Wu, Xiaoting Wu, Dijia Zhou, Tengmei Lin, Saidan Ding, Yu Zhang, Jiangnan Xue*Qichuan Zhuge*
Affiliation:
- Department of Immunology, Binzhou Medical University, Yantai,China
- Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000,China
Keywords: Metabolic regulator/housekeeper, XBP1, PI3K, ER stress, IRE1α, insulin.
Abstract: X-box binding protein1 (XBP1) especially exerts its fundamental effects in the cellular organelle endoplasmic reticulum (ER) via affecting three trans-membrane stress sensor proteins: PKRlike ER kinase (PERK), inositol-requiring enzyme 1(IRE1) and activating transcription factor 6(ATF6). At the center of XBP1’s broad effects is its remarkable metabolic housekeeper function. XBP1 decreased glucose dysfunction via funneling its effects on improving insulin sensitivity and stimulating insulin secretion. However, XBP1 also yields its double-edged effects, driving the transformation from excess glucose to lipid, which is a key contribution to obesity and T2DM. In this review, we highlight the vital mechanism of XBP1 in manipulating glucose and lipid metabolism involved by multiple signaling pathways.
Export Options
About this article
Cite this article as:
Yang Jianjing, Wu Xiaojie, Wu Xiaoting, Zhou Dijia, Lin Tengmei, Ding Saidan, Zhang Yu, Xue Jiangnan*, Zhuge Qichuan*, The Multiple Roles of XBP1 in Regulation of Glucose and Lipid Metabolism, Current Protein & Peptide Science 2017; 18 (6) . https://dx.doi.org/10.2174/1389203717666160627085011
DOI https://dx.doi.org/10.2174/1389203717666160627085011 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin I-Converting Enzyme: A Pathogenetic Role in Diabetic Renal Damage?
Current Diabetes Reviews Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Regulation of Catechins in Uric Acid Metabolism Disorder Related Human Diseases
Mini-Reviews in Medicinal Chemistry Raxofelast, (±)5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic Acid: A New Antioxidant to Modulate the Inflammatory Response During Ischemia-Reperfusion Injury and Impaired Wound Healing
Mini-Reviews in Medicinal Chemistry Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design Review of Medicinal Plants and their Compounds for Aldose Reductase Inhibitory Activity
Letters in Drug Design & Discovery Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Erectile Dysfunction and Diabetes Mellitus: Mechanistic Considerations from Studies in Experimental Models
Current Diabetes Reviews Angiotensin Type 1 Receptor Blockers in Heart Failure
Current Drug Targets New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials Microalbuminuria In Primary Hypertension
Current Hypertension Reviews Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology